REFERENCE
1. Saba V. Estimation of Age Standardized Ratio of Lung Cancer
in Iran in 2014 and 2030. Paramed Sci Military Health.
2015;10(1):17-23.
2. Patel JD, Bach PB, Kris MG. Lung cancer in US women: a
contemporary epidemic. JAMA. 2004;291(14):1763-1768.
doi: 10.1001/jama.291.14.1763 pmid: 15082704
3. Barbone F, Bovenzi M, Cavallieri F, Stanta G. Cigarette
smoking and histologic type of lung cancer in men. Chest.
1997;112(6):1474-1479. doi: 10.1378/chest.112.6.1474
pmid: 9404741
4. Boffetta P, Nyberg F. Contribution of environmental factors to
cancer risk. Br Med Bull. 2003;68:71-94. doi:
10.1093/bmp/ldg023 pmid: 14757710
5. Pecorino L. Molecular biology of cancer: mechanisms, targets,
and therapeutics: Oxford university press; 2012.
6. Jancik S, Drabek J, Radzioch D, Hajduch M. Clinical relevance
of KRAS in human cancers. J Biomed Biotechnol.
2010;2010:150960. doi: 10.1155/2010/150960 pmid:
20617134
7. Krystal GW, Honsawek S, Litz J, Buchdunger E. The selective
tyrosine kinase inhibitor STI571 inhibits small cell lung cancer
growth. Clin Cancer Res. 2000;6(8):3319-3326. pmid:
10955819
8. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-
354825) tyrosine kinase inhibitor suppresses invasion and
induces cell cycle arrest and apoptosis of head and neck
squamous cell carcinoma and non-small cell lung cancer cells.
Clin Cancer Res. 2005;11(19 Pt 1):6924-6932. doi:
10.1158/1078-0432.CCR-05-0757 pmid: 16203784
9. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell
lung cancer. Proc Am Thorac Soc. 2009;6(2):201-205. doi:
10.1513/pats.200809-107LC pmid: 19349489
10. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D,
Tuveson DA, et al. Somatic activation of the K-ras oncogene
causes early onset lung cancer in mice. Nature.
2001;410(6832):1111-1116. doi: 10.1038/35074129 pmid:
11323676
11. Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS,
Chitale D, et al. Genomic and biological characterization of
exon 4 KRAS mutations in human cancer. Cancer Res.
2010;70(14):5901-5911. doi: 10.1158/0008-5472.CAN-10-
0192 pmid: 20570890
12. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA.
Personalized medicine in non-small-cell lung cancer: is KRAS
a useful marker in selecting patients for epidermal growth
factor receptor-targeted therapy? J Clin Oncol.
2010;28(31):4769-4777. doi: 10.1200/JCO.2009.27.4365
pmid: 20921461
13. Jazi MS, Zahri S, Navid SL, Talebi A. Relationship between
common KRAS gene mutations and clinicopathological
features of patients with colorectal cancer in Isfahan, Iran.
Govaresh. 2017;22(1):39-46.
14. Gultekin MA, Turk HM, Besiroglu M, Toprak H, Yurtsever I,
Yilmaz TF, et al. Relationship between KRAS mutation and
diffusion weighted imaging in colorectal liver metastases;
Preliminary study. Eur J Radiol. 2020;125:108895. doi:
10.1016/j.ejrad.2020.108895 pmid: 32109834
15. Zheng D, Wang R, Zhang Y, Pan Y, Cheng X, Cheng C, et al.
The prevalence and prognostic significance of KRAS mutation
subtypes in lung adenocarcinomas from Chinese populations.
Onco Targets Ther. 2016;9:833-843. doi:
10.2147/OTT.S96834 pmid: 26955281.
